Our results suggest that TLR13 recruits and phosphorylates IRF3 to inhibit AKT activity and impaired insulin signaling, thereby mediating the occurrence of CKD skeletal muscle atrophy. The gene discussed is AKT1; the disease is chronic kidney disease.